Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Sickle-Cell Anemia

Sickle-Cell Anemia

Part of Anemia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Sickle-Cell Anemia

34 trials tracked for Sickle-Cell Anemia: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 808 citations.

34Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 5 Phase 2 15 Phase 1 3 Other / NA 9
  1. Phase 3 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Completed · 808 cited
  2. Phase 3 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia Completed · 563 cited
  3. Phase 3 Novel Use Of Hydroxyurea in an African Region With Malaria Completed · 148 cited
  4. Phase 3 Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Completed · 50 cited
  5. Phase 4 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed
  6. Phase 4 Actigraphy Improvement With Voxelotor (ActIVe) Study Completed
Show 28 more trials
  1. Phase 3 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial Completed
  2. Phase 2 Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies Completed
  3. Phase 2 Hydroxyurea and EPO in Sickle Cell Disease Completed
  4. Phase 2 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed
  5. Phase 2 L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia Completed
  6. Phase 2 The Effect of Rivaroxaban in Sickle Cell Disease Completed
  7. Phase 2 Daily Vitamin D for Sickle-cell Respiratory Complications Completed
  8. Phase 2 Management of Severe Acute Malnutrition in SCD, in Northern Nigeria Completed
  9. Phase 2 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia Completed
  10. Phase 2 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Completed
  11. Phase 2 A Phase II Trial of Regadenoson in Sickle Cell Anemia Completed
  12. Phase 2 Losartan to Reverse Sickle Nephropathy Completed
  13. Phase 2 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease Completed
  14. Phase 2 Prasugrel Versus Placebo in Adult Sickle Cell Disease Completed
  15. Phase 2 Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Completed
  16. Phase 2 Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers Completed
  17. Phase 1 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults Completed
  18. Phase 1 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease Completed
  19. Phase 1 A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers Completed
  20. N/A Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Completed
  21. N/A Evaluation of the AMICUS RBCx System in Sickle Cell Patients Completed
  22. N/A Decision Aid for Therapeutic Options In Sickle Cell Disease Completed
  23. N/A Shared-Decision Making for Hydroxyurea Completed
  24. N/A Microvascular Blood Flow in Sickle Cell Anemia Completed
  25. N/A Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol Completed
  26. N/A Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study) Completed
  27. N/A Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease Completed
  28. N/A Carbon Monoxide Measurement to Screen for Sickle Cell Disease Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Sickle-Cell Anemia: what the trials found

Hydroxyurea treatment is associated with significant improvements in hemoglobin levels and fetal hemoglobin percentages. Specifically, patients showed a median increase in fetal hemoglobin of 1.70% to 8.00% (p=0.0005) and mean hemoglobin increases ranging from 0.42 to 1.15 g/dL (p=0.033) 12. Additionally, a specific cohort showed a 15% response rate in the percentage of participants with a hemoglobin response 1.

L-glutamine has been shown to significantly reduce the number of sickle cell crises (p=0.0052) and hospitalizations for sickle cell pain (p=0.0045) 5. While another trial observed similar trends in crisis occurrences, hospitalization frequency, and emergency room visits, these specific outcomes did not reach statistical significance 13.

Voxelotor demonstrated a 41.7% success rate for patients achieving a >1 g/dL increase in hemoglobin at week 12, which decreased to 26.1% by week 24 2. Other interventions like Rivipansel did not show statistically significant differences in time to discharge or cumulative IV opioid consumption 7.

Fentanyl Citrate was associated with a significant reduction in pain scores (p=0.048) and a lower incidence of headaches (p=0.05) compared to the control group 3. Transfusion therapy is also established as an intervention for this condition 8.

Recent results — preliminary, needs further review

  • Daily oral vitamin D3 (3,333 IU) was evaluated regarding the ratio of residual lung volume to total lung capacity, though specific significance was not noted in the provided data 9.

For the clinician treating this condition

  • Hydroxyurea is supported by evidence for increasing both hemoglobin and fetal hemoglobin levels 12.
  • L-glutamine may be effective in reducing the frequency of sickle cell crises and associated hospitalizations 5.
  • Voxelotor shows a measurable impact on hemoglobin levels at 12 weeks, though this effect appears to diminish by week 24 2.
  • Fentanyl Citrate is associated with improved pain scores and reduced headache incidence in clinical settings 3.

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration
Genetics & Precision Medicine Sys. Review
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration First CRISPR gene therapy approved for blood disorders, with broader research underway
A systematic review of clinical trials registered at clinicaltrials.gov found the first CRISPR-Cas9 therapy obtained FDA approval in late 20…
The first CRISPR gene therapy is approved for sickle-cell anemia and β-thalassemia, with ongoing trials exploring its use for cancer and inf…
Frontiers Apr 3, 2026
Report examines use of recommended health care measures for sickle cell anemia complications in youth
Hematology
Report examines use of recommended health care measures for sickle cell anemia complications in youth Report examines use of preventive care for children with sickle cell anemia
A report describes the use of recommended health care measures to prevent complications of sickle cell anemia in children and adolescents in…
A new report looked at how children and adolescents with sickle cell anemia in the U.S.
CDC Apr 2, 2026

Research across Anemia

Related studies from across the Anemia family.

Local ancestry-aware GWAS finds 38 European-tract and 12 African-tract loci for eGFR in sickle cell disease
Hematology Meta-analysis
Local ancestry-aware GWAS finds 38 European-tract and 12 African-tract loci for eGFR in sickle cell disease New genetic markers may help identify kidney damage in sickle cell disease
This genome-wide association meta-analysis used local ancestry-aware analysis to identify genomic regions linked to estimated glomerular fil…
Researchers identified specific genetic regions that may help doctors spot and treat kidney issues in people with sickle cell disease earlie…
Oct 27, 2026
CHIP prevalence is 8.5% in adults and associated with higher systemic immune-inflammation index
Genetics & Precision Medicine Meta-analysis
CHIP prevalence is 8.5% in adults and associated with higher systemic immune-inflammation index Large study links blood mutations to heart and lung risks
This meta-analysis of a multi-ancestry cohort of 59,598 adults identifies a 8.5% prevalence of clonal hematopoiesis of indeterminate potenti…
A large study of over 59,000 people found that specific blood mutations, known as CHIP, are linked to heart, lung, and blood cancer risks.
medRxiv Oct 26, 2026
Mitapivat Improves Haemoglobin Concentration in Patients with Chronic Sickle Cell Disease
Hematology RCT
Mitapivat Improves Haemoglobin Concentration in Patients with Chronic Sickle Cell Disease Trial shows mitapivat improves hemoglobin in sickle cell disease
Mitapivat demonstrated a significant increase in haemoglobin levels for patients with sickle cell disease in this Phase 3 trial.
A new clinical trial shows that mitapivat significantly improves hemoglobin levels for adults and older teens with sickle cell disease.
Oct 24, 2026
Forty independent genetic loci associated with acute chest syndrome occurrence in sickle cell disease patients
Hematology Meta-analysis
Forty independent genetic loci associated with acute chest syndrome occurrence in sickle cell disease patients Identifying Genetic Markers Linked to Chest Problems in Sickle Cell Disease
This meta-analysis of genetic variants in patients with sickle cell disease identified 40 independent genetic loci associated with acute che…
New research identifies specific genetic markers that may help predict and manage serious chest complications in patients with sickle cell d…
medRxiv Oct 19, 2026
Ultraprocessed food intake is associated with lower sTfR concentrations in rural Ghanaian schoolgirls
Pediatrics RCT
Ultraprocessed food intake is associated with lower sTfR concentrations in rural Ghanaian schoolgirls Ultraprocessed foods linked to lower iron markers in schoolgirls
This randomized controlled trial secondary analysis of 300 rural Ghanaian adolescent schoolgirls found that ultraprocessed food intake was a…
Eating more ultraprocessed foods is linked to lower iron markers in schoolgirls, while whole foods show a positive link to iron levels.
Oct 10, 2026
Sickle cell trait is associated with increased risk of kidney disease, pulmonary embolism, and anemia
Hematology Meta-analysis
Sickle cell trait is associated with increased risk of kidney disease, pulmonary embolism, and anemia Sickle cell trait linked to higher risks of kidney and blood issues
This meta-analysis analyzed 4,813 individuals with sickle cell trait (SCT) to identify phenome-wide and laboratory-wide associations. The st…
New data shows that people with sickle cell trait may face higher risks for kidney disease, anemia, and other serious health conditions.
Oct 2, 2026
RBC alloimmunization affects 8.76% of transfused sickle cell patients in resource-limited settings
Hematology Meta-analysis
RBC alloimmunization affects 8.76% of transfused sickle cell patients in resource-limited settings New data shows common risks for sickle cell disease patients
This meta-analysis pooled data from 3128 patients with sickle cell disease who received red blood cell transfusions in resource-limited coun…
New data reveals that nearly 9% of sickle cell patients who receive blood transfusions develop a common immune reaction.
Oct 1, 2026
Preoperative anaemia increases risk of red cell transfusion and acute kidney injury in cardiac surgery
Cardiology Meta-analysis
Preoperative anaemia increases risk of red cell transfusion and acute kidney injury in cardiac surgery Preoperative Anaemia Linked to Higher Risks During Cardiac Surgery
This meta-analysis of observational cohort studies involving 74,571 adults undergoing cardiac surgery found that preoperative anaemia is ass…
Patients with anemia before heart surgery may face higher risks of kidney issues, infections, and the need for blood transfusions.
medRxiv Oct 1, 2026
Heart Failure Evidence in Somalia Is Fragmented and Insufficient to Estimate National Burden
Cardiology Meta-analysis
Heart Failure Evidence in Somalia Is Fragmented and Insufficient to Estimate National Burden Review Identifies Common Causes of Heart Failure in Somalia
This scoping review synthesizes 12 studies on heart failure in Somalia, finding that evidence is geographically concentrated, methodological…
A review of 12 studies identifies key conditions like hypertension and heart disease that contribute to heart failure in the Somali region.
Frontiers Sep 29, 2026
Integrated haemotherapeutic systems improve transfusion safety and sustainability for sickle cell disease patients in Africa
Rheumatology Sys. Review
Integrated haemotherapeutic systems improve transfusion safety and sustainability for sickle cell disease patients in Africa New strategies aim to improve blood safety for sickle cell disease
This narrative review synthesizes current challenges and proposed solutions for sickle cell disease haemotherapy in Africa. The authors argu…
Newer strategies for blood management aim to solve common problems like blood shortages and infection risks for people with sickle cell dise…
Frontiers Sep 25, 2026
Integrated Intervention Improves Weight and Reduces Anemia in Term SGA Infants
Pediatrics RCT
Integrated Intervention Improves Weight and Reduces Anemia in Term SGA Infants Integrated care package improves growth in small-for-gestational-age infants
This randomized trial in 1300 term small-for-gestational-age infants in South Delhi found that an integrated health, nutrition, stimulation,…
A combined program of nutrition, health, and early stimulation helped small-for-gestational-age infants achieve better weight and growth out…
JAMA Sep 23, 2026
Chronic pain in aging adults with sickle cell disease shifts toward persistent, multifactorial syndromes
Cardiology Sys. Review
Chronic pain in aging adults with sickle cell disease shifts toward persistent, multifactorial syndromes Sickle Cell Pain Changes With Age, Review Finds
This narrative review examines the pathophysiology and management of chronic pain in aging adults with sickle cell disease. The authors conc…
Sickle cell pain isn't just crises anymore. As patients age, it becomes persistent and driven by organ damage, a review finds.
Frontiers Sep 23, 2026